Literature DB >> 24903792

Outbreak of pyrazinamide-monoresistant tuberculosis identified using genotype cluster and social media analysis.

T A Thomas1, S K Heysell1, E R Houpt1, J L Moore2, S J Keller2.   

Abstract

SETTING: Monoresistance to pyrazinamide (PZA) has infrequently been associated with Mycobacterium tuberculosis.
OBJECTIVE: To report an outbreak of PZA-monoresistant M. tuberculosis in Virginia involving two genotype clusters from December 2004 to August 2010.
RESULTS: Thirty cases were identified involving a predominantly young, US-born population with histories of substance use and incarceration and a large proportion of children aged <15 years (n= 6, 20%); of these, 23 cases (77%) were culture-confirmed as M. tuberculosis complex. DNA fingerprinting and molecular analysis of the PZA resistance gene, pncA, demonstrated a clonal strain that was not M. bovis. Genotypic data provided the initial link between seemingly unrelated cases, and helped reveal a historic genotype cluster of cases from 2004. Further genotype cluster and contact investigation procedures, including the novel use of the social networking website Facebook.com, revealed additional links between the 2004 and 2009 genotype clusters and described an ongoing, extensive outbreak necessitating an enhanced screening and treatment protocol for contacts.
CONCLUSIONS: This outbreak demonstrates how tuberculosis can spread through a young, vulnerable population. The use of genotypic data and the novel incorporation of social media investigations were critical to understanding the settings and context of infectivity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24903792      PMCID: PMC4382754          DOI: 10.5588/ijtld.13.0663

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  23 in total

1.  Missed opportunities for preventing tuberculosis among children younger than five years of age.

Authors:  M N Lobato; J C Mohle-Boetani; S E Royce
Journal:  Pediatrics       Date:  2000-12       Impact factor: 7.124

2.  Treatment of tuberculosis.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2003-06-20

3.  Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States.

Authors:  M M Hannan; E P Desmond; G P Morlock; G H Mazurek; J T Crawford
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

4.  pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.

Authors:  S J Cheng; L Thibert; T Sanchez; L Heifets; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis?

Authors:  Bouke C de Jong; Anthony Onipede; Alex S Pym; Sebastien Gagneux; Roxanne S Aga; Kathryn DeRiemer; Peter M Small
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

6.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system.

Authors:  Gaby E Pfyffer; Frantiska Palicova; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

7.  Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms.

Authors:  S Sreevatsan; X Pan; Y Zhang; B N Kreiswirth; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

8.  Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2005-12-16

9.  Epidemiology of pediatric tuberculosis using traditional and molecular techniques: Houston, Texas.

Authors:  Susan H Wootton; Blanca E Gonzalez; Rebecca Pawlak; Larry D Teeter; Kim Connelly Smith; James M Musser; Jeffrey R Starke; Edward A Graviss
Journal:  Pediatrics       Date:  2005-11       Impact factor: 7.124

10.  Widespread pyrazinamide-resistant Mycobacterium tuberculosis family in a low-incidence setting.

Authors:  Dao Nguyen; Paul Brassard; Jennifer Westley; Louise Thibert; Melanie Proulx; Kevin Henry; Kevin Schwartzman; Dick Menzies; Marcel A Behr
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more
  5 in total

Review 1.  Tuberculosis in Adolescents and Young Adults: Emerging Data on TB Transmission and Prevention among Vulnerable Young People.

Authors:  Katherine M Laycock; Leslie A Enane; Andrew P Steenhoff
Journal:  Trop Med Infect Dis       Date:  2021-08-05

2.  Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.

Authors:  Sarah Sengstake; Indra L Bergval; Anja R Schuitema; Jessica L de Beer; Jody Phelan; Rina de Zwaan; Taane G Clark; Dick van Soolingen; Richard M Anthony
Journal:  BMC Infect Dis       Date:  2017-07-12       Impact factor: 3.090

Review 3.  The potential use of social media and other internet-related data and communications for child maltreatment surveillance and epidemiological research: Scoping review and recommendations.

Authors:  Laura M Schwab-Reese; Wendy Hovdestad; Lil Tonmyr; John Fluke
Journal:  Child Abuse Negl       Date:  2018-02-01

4.  Tuberculosis Outbreak Associated With Delayed Diagnosis and Long Infectious Periods in Rural Arkansas, 2010-2018.

Authors:  Sarah M Labuda; Clinton J McDaniel; Amish Talwar; Anthwan Braumuller; Sarah Parker; Stephanie McGaha; Carolynne Blissett; Jonathan M Wortham; Leonard Mukasa; Rebekah J Stewart
Journal:  Public Health Rep       Date:  2021-03-17       Impact factor: 2.792

5.  Evolutionary History and Ongoing Transmission of Phylogenetic Sublineages of Mycobacterium tuberculosis Beijing Genotype in China.

Authors:  Qing-Qin Yin; Hai-Can Liu; Wei-Wei Jiao; Qin-Jing Li; Rui Han; Jian-Ling Tian; Zhi-Guang Liu; Xiu-Qin Zhao; Ying-Jia Li; Kang-Lin Wan; A-Dong Shen; Igor Mokrousov
Journal:  Sci Rep       Date:  2016-09-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.